IL13 and airway hyperresponsiveness: In the study by Serajeddini et al. [22], dupilumab was added to anti-IL-5 mAB when elevated FeNO, airway smooth muscle dysfunction, and severe airway hyperresponsiveness (AHR), all signs of IL-4/IL-13 inflammation, were present, determining uncontrolled asthma symptoms.